Covid19 Clinical Trial
Official title:
Development and Persistence of Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients in Comparison With Immunocompetent Patients
This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.
The liver transplant (HT) recipient population is more susceptible to infections than the
general population. Few data are available regarding the incidence and clinical course of
SARS-CoV-2 infection in this population, initially considered to be "high risk" regarding a
possible higher incidence and severity of infection in these patients.
A prospective cohort of liver transplant recipient patients diagnosed with SARS-CoV-2
infection (Clinical Trials.gov Protocol Record HCB / 2020/0384) has been developed from SETH
(Spanish Society for Liver Transplantation). This study aims to analyze the incidence and
establish the clinical evolution of the infection in these patients. Initial data from the
cohort, which includes 111 incidental cases diagnosed as of April 7, show a higher
standardized incidence than the general population, but not higher mortality (data being
published).
The chronic immunosuppression in t solid organ transplant patients could play a double role
with respect to SARS-Cov-2 infection: on the one hand, it may condition a greater
susceptibility and initial aggressiveness, in relation to itself viral effect, and in the
other hand, it could protect by reducing the immune response that triggers the pulmonary and
systemic inflammatory process.
After the initial Covid-19 outbreak, both in the general population and in immunosuppressed
patients, the rate of specific IgM and IgG seroconversion against this coronavirus, and its
protective capacity against reactivations or reinfections, are unknown. Therefore, it is a
challenge for health organizations to identify the immune response in the population and to
characterize its degree of protection, to adopt early measures to lessen the consequences of
possible epidemic waves in the coming months.
Continuing with the prospective study of the cohort of liver transplant patients diagnosed
with Covid-19 (SETH-Covid-19), already defined and composed of 91 living patients, the
humoral immune response and its evolution in the first 12 months after initial infection. The
cohort will incorporate the new incidental cases; A comparative study will be carried out
with a contemporary cohort of non-immunosuppressed patients, controlled for age, gender and
severity of the initial disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |